Debiopharm S.A. and Dyax Corp. granted orphan drug designation for DX-890 (EPI-HNE4) by U.S. FDA – Cystic Fibrosis designation
Debiopharm S.A. seeks New Partner to Commercialise Trelstar® (Triptorelin Pamoate) in the US, Canada and Mexico for the Treatment of…
Debiopharm presents results of a first monthly injectable sustained-release fomulation of ZT-1 for Alzheimer´s Disease
Debiopharm and Tulane Cancer Center select Hemenway as the 2003 Mauvernay Research Excellence Scholar
Debiopharm SA starts a Phase II trial for a once daily oral formulation of ZT-1 to treat Alzheimer´s
Debiopharm S.A. and Dyax Corp. granted European Orphan Drug Status for EPI-hNE4 (DX-890) for Cystic Fibrosis Indication
H3 Pharma Inc. announces important step in bringing SANVAR® (vapreotide) to U.S. market
H3 Pharma Inc. Licenses in Sanvar ® (vapreotide) from Debiopharm S.A.
DEBIOPHARM S.A. licenses-in a compound from Genodyssee S.A.